ReviewJournal of neurochemistry2025
Extracellular Vesicles as Therapeutic Strategy for Ischemic Stroke.
Review in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neurovascular Unit-Derived Extracellular Vesicles as Regulators of Post-Stroke Pathology and Neurorestoration.Biomolecules · 2026Review
- The Dual Role of Extracellular Vesicles in Aging and Age-Related Diseases: Pathophysiology and Therapeutic Potential.International journal of nanomedicine · 2026Review
- Extracellular Vesicles as Therapeutic Strategy for Ischemic Stroke.Journal of neurochemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ischemic stroke remains one of the leading causes of death and long-term disability worldwide, with current treatments limited by narrow therapeutic windows and the risk of hemorrhagic transformation. In this context, extracellular vesicles (EVs) have emerged as a promising cell-free therapeutic strategy due to their ability to modulate inflammation and support neuroregeneration. This review explores recent advances in the application of EVs in ischemic stroke therapy, highlighting their mechanisms of action, including the delivery of neuroprotective molecules such as microRNAs and proteins that promote angiogenesis, neurogenesis, and anti-apoptotic pathways. We summarize findings from preclinical models demonstrating the regenerative potential of EVs derived from mesenchymal stem cells, microglia, neural progenitor cells, and other cell types, as well as advances in bioengineered EVs for targeted delivery. Despite encouraging results, the clinical translation of EV-based therapies faces challenges, including large-scale production, content variability, and targeted delivery efficiency. Future efforts should focus on optimizing EV characterization and manufacturing processes to ensure therapeutic consistency and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.